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Death Receptor 5, a New Member of the TNFR
Family, and DR4 Induce FADD-Dependent Apoptosis
and Activate the NF-kB Pathway
a C-terminal death domain through which it binds to the
death domain of Fas/Apo-1 (Boldin et al., 1995; Chinnai-
yan et al., 1995). Despite its sequence homology to the
similar domains present in the death domain±containing
receptors, the death domain of FADD cannot induce
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in fact, can block the apoptosis mediated by Fas and
TNFR1 in a dominant-negative fashion (Chinnaiyan et
al., 1995; Hsu et al., 1996b). FADD possesses anotherSummary
domain called the death effector domain at its N termi-
nus, which can induce apoptosis when overexpressedDeath receptor4 (DR4) is a recently described receptor
in mammalian cells (Chinnaiyan et al., 1995; Hsu et al.,for the cytotoxic ligand TRAIL that reportedly uses a
1996b). Through its death effector domain, FADD bindsFADD-independent pathway to induce apoptosis and
to the proapoptotic apical caspase, Caspase 8 (alsodoes not activate the NF-kB pathway. We have iso-
called FLICE, MACH, or Mch5) (Boldin et al., 1996; Fer-lated a new member of the tumor necrosis factor re-
nandes-Alnemri et al., 1996; Muzio et al., 1996). Caspaseceptor (TNFR) family, designated DR5, which bears a
8 is the most proximal caspase in the cascade of cas-high degree of sequence homology to DR4. However,
pase, activation of which eventually leads to cell deathcontrary to the previous reports, both DR4- and DR5-
(Boldin et al., 1996; Fernandes-Alnemri et al., 1996;induced apoptosis can be blocked by dominant-nega-
Muzio et al., 1996). While Fas/Apo-1 can bind directlytive FADD, and both receptors can activate NF-kB
to FADD, it is generally believed that TNFR1 and DR3using a TRADD-dependent pathway. Finally, both re-
bind to FADD via the intermediate death domain±ceptors can interact with FADD, TRADD, and RIP.
containing adapter molecule TRADD (Chinnaiyan et al.,Thus, both DR5 and DR4 use FADD, TRADD, and RIP
1996a, 1996b; Hsu et al., 1996b; Kitson et al., 1996).in their signal transduction pathways, and FADD is the
Thus, FADD is the final common link between the deathcommon mediator of apoptosis by all known death
domain±containing receptors Fas/Apo-1, TNFR1 anddomain±containing receptors.
DR3, and Caspase 8 (Boldin et al., 1995; Chinnaiyan et
al., 1995, 1996a, 1996b; Hsu et al., 1996b; Kitson et al.,
Introduction
1996).
In addition to recruiting FADD, TRADD recruits two
The tumor necrosis factor receptor (TNFR) family of pro- additional molecules to the aggregated receptor com-
teins plays an important role in the mediation of apo- plex of TNFR1 or DR3: the death domain±containing
ptosis or programmed cell death in diverse biological protein RIP and TRAF2, which lacks a death domain
systems (Smith et al., 1994; Gruss and Dower, 1995; (Hsu et al., 1995, 1996a, 1996b). While recruitment of
Baker and Reddy, 1996). These type 1 membrane proteins FADD leads to activation of caspases and eventual cell
share significant sequence homology in their extracellu- death, recruitment of RIP and TRAF2 leads to the activa-
lar domains, owing to the presence of highly conserved tion of the NF-kB pathway, which may protect cells from
cysteine residues in the cysteine-rich pseudorepeats, a TNF-induced apoptosis (Beg and Baltimore, 1996; Hsu
hallmark of this family (Smith et al., 1994; Gruss and et al., 1996a, 1996b; Liu et al., 1996; Van Antwerp et al.,
Dower, 1995; Baker and Reddy, 1996). In addition, three 1996; Wang et al., 1996).
members of this family, TNFR1, Fas/Apo-1 (CD95), and DR4 is the most recently described death domain±
death receptor 3 (DR3) (also called Wsl-1, Apo-3, and containing receptor and was shown to be the receptor
TRAMP), possess a conserved domain of approximately for the cytotoxic ligand TRAIL (Apo-2 ligand) (Pan et
80 amino acids near their C terminal called the death al., 1997a). It was reported that DR4-induced apoptosis
domain, which is required for induction of apoptosis by cannot be blocked by dominant-negative FADD, and
these receptors (Itoh and Nagata, 1993; Tartaglia et al., DR4 cannot coimmunoprecipitate FADD, TRADD, or RIP
1993; Cleveland and Ihle, 1995; Chinnaiyan et al., 1996a; (Pan et al., 1997a). These results are in agreement with
Kitson et al., 1996; Marsters et al., 1996; Bodmer et al., a previous report of the inability of dominant-negative
1997). FADD to block TRAIL-induced apoptosis (Marsters et
Death domains are also found in Fas-associating pro- al., 1996) and led to the conclusion that DR4 is unique
tein with death domain (FADD) (or MORT1), TNFR1- among the death domain±containing receptors in using
associated death domain (TRADD), and receptor-inter- a FADD-independent pathway to activatecaspases (Pan
acting protein (RIP), three cytoplasmic adapter proteins et al., 1997a). In the same study it was reported that
implicated in the mediation of apoptosis by the death DR4 is incapable of activating the NF-kB pathway (Pan
domain±containing receptors (Boldin et al., 1995; Chin- et al., 1997a).
naiyan et al., 1995; Hsu et al., 1995, 1996a; Stanger et During the course of investigating a new death do-
al., 1995). FADD is an adapter molecule that possesses main±containing receptor designated DR5, we discov-
ered that while it resembled DR4 in overall structure, it
resembled TNFR1 and DR3 in using FADD and NF-kB*To whom correspondence should be addressed (e-mail: molbiotk
@u.washington.edu). as mediators of its signal transduction pathway. This
Immunity
822
led to a comparative analysis of the signal transduction we tested the ability of DR5 to induce apoptosis in
MCF7, a human breast carcinoma cell line; 293T, a sub-pathways utilized by DR5, DR4, and DR3, which is the
focus of the present study. clone of human embryonic kidney cells; and BHK, a
baby hamster kidney cell line. Transient transfection of
a full-length DR5 construct induced rapid apoptosis inResults
all three cell lines tested (Figure 3A and data not shown).
Two C-terminal deletion mutants of DR5, lacking eitherMolecular Cloning and Sequence Analysis of DR5
the cytoplasmic tail (DR5DCP) or the death domainTwo human expressed sequence tag (EST) clones (IMAGE
(DR5DDD), failed to induce apoptosis, indicating thatConsortium clones 650744 and 664665) were found to
the death domain is essential for transmitting the deathhave statistically significant homology to the extracellu-
signal (Figure 3A). A mutant construct, containing a leu-lar domain of human TNFR1. To obtain the full-length
cine-to-asparagine substitution at amino acid 334 (DR5-clone, 59 and 39 rapid amplification of cDNA ends (RACE)
L334N), also failed to induce apoptosis (Figure 3A). Thus,was used. The full-length clone was designated DR5
like other death domain±containing receptors, aminoand encoded a protein of 411 amino acids with charac-
acid L334, which corresponds to the site of lpr mutation,teristics of a cell-surface receptor, including a signal
is essential for signaling apoptosis by DR5 (Watanabe-peptide of 51 amino acids at the beginning and a trans-
Fukunaga et al., 1992; Itoh and Nagata, 1993; Tartagliamembrane region of 23 amino acids (residues 183±205)
et al., 1993; Kitson et al., 1996).present in the middle (Figure 1A). The initiating methio-
nine was surrounded by the sequence CCGCCATGG,
which is highly homologous to the consensus Kozak Dominant-Negative FADD Can Block Apoptosis
sequence CCA/GCCATGG (1996). An in-frame stop co- by DR5 and DR4
don present 10 amino acids upstream of this methionine Mediation of apoptosis by the death domain±containing
established it as the true start site (data not shown). The receptors TNFR1, Fas, and DR3 involves recruitment of
extracellular domain contained cysteine-rich pseudore- the adapter molecule FADD/MORT1 either directly or
peats, a hallmark of theTNFR family, and had the highest via an intermediate adapter molecule TRADD (Boldin et
degree of homology to DR4 (58% identity and 70% simi- al., 1995; Chinnaiyan et al., 1995, 1996a, 1996b; Hsu et
larity) (Figure 1A). The extracellular domain also shared al., 1995, 1996b). Two recent studies, however, suggest
weaker homology with TNFR1 (27% identity and 46% that DR4 uses a unique and distinct FADD-independent
similarity), Fas (25% identity and 45% similarity), DR3 pathway to transmit its death signal (Marsters et al.,
(21% identity and 40% similarity), and other members 1996; Pan et al., 1997a). This conclusion is based on
of the TNFR family. DR5 has a cytoplasmic tail of 212 the inability of a dominant-negative mutant of FADD
amino acids, with a death domain near its C terminus (DN-FADD) to block apoptosis mediated by DR4 effec-
possessing significant sequence homology to the death tively and the inability of DR4 to coimmunoprecipitate
domains of DR4, TNFR1, DR3, and Fas (Figure 1B). In FADD or TRADD (Pan et al., 1997a). As DR5 bears a
addition, several amino acids, which have been shown high degree of sequence homology to DR4 in its cyto-
to be essential for death signaling by TNFR1 and Fas/ plasmic tail, including the death domain, we had ex-
Apo-1 (Itoh and Nagata, 1993; Tartaglia et al., 1993), are pected it also to act independently of FADD. Surpris-
also conserved in the death domain of DR5 (Figure 1B). ingly, DN-FADD (amino acids 80-208) was able to
This includes amino acid L334, corresponding to the partially block apoptosis mediated by DR5 in MCF7 cells
site of lpr mutation in the mouse Fas receptor (Figure (Figure 3B). To resolve the discrepancy between our
1B) (Watanabe-Fukunaga et al., 1992). study and the published reports, we tested the ability
Alignment of the protein sequences of DR5 and DR4 of increasing amounts of DN-FADD to block apoptosis
revealed that methionine at position 59 might represent mediated by DR3, DR4, and DR5 in 293T cells. DR3
the true start site for DR4 (Figure 1A). Similarly, the true possesses a death domain highly homologous to TNFR1,
signal peptide for DR4 might lie between amino acid and like TNFR1, its apoptosis can be blocked by DN-
residues 59-109 (Figure 1A). This conclusion was sup- FADD (Chinnaiyan et al., 1996a). Increasing amounts of
ported by the hydrophobicity plots, which revealed a DN-FADD led to progressive inhibition of apoptosis by
highly hydrophobic segment between amino acids 32- all three receptors, with almost complete inhibition of
49 and 86-104 for DR5 and DR4, respectively (Figure 1C). apoptosis seen at a receptor to DN-FADD ratio of 1:10
in all the three cases (Figures 3C, 3D, and 3E). These
results indicate that contrary to the previous reports,Expression of DR5
DR4 and DR5 also mediate apoptosis by a FADD-depen-Tissue distribution of DR5 revealed the presence of a
dent pathway. Hence, all known death domain±contain-major transcript of approximately 4.4 kb, present in all
ing receptors use FADD as the final common link withtissues tested, including spleen, thymus, prostate, tes-
the downstream apoptotic caspases.tis, ovary, small intestine, colon mucosa, and peripheral
blood leukocytes (Figure 2).
DR5 and DR4 Induce Apoptosis by a
Caspase-Dependent MechanismOverexpression of DR5 Induces Apoptosis
in Mammalian Cells The next step in the mediation of death signal by Fas,
TNFR1, and DR3 is the recruitment of the interleukin-Overexpression of death domain±containing receptors
can induce apoptosis in a ligand-independent manner 1b-converting enzyme- like protease Caspase 8 (FLICE/
MACH1) by FADD to the aggregated death receptor(Boldin et al., 1995; Chinnaiyan et al., 1996a). Therefore,
DR5, a New Member of the TNFR Family
823
Figure 1. The Nucleotide and Predicted Amino Acid Sequences of DR5 and Sequence Analysis
(A) The predicted amino acid sequence of DR5 is aligned with the sequence of DR4. Black; identical amino acids; gray, homologous residues.
The positions of the predicted signal peptides, transmembrane regions, and the death domains are shown above and below the sequences
of DR5 and DR4, respectively. Unlike the report by Pan et al. (1997a), the start site is numbered as amino acid 1.
(B) Sequence alignment of the death domains of DR5, DR4, DR3, TNFR1, and Fas/Apo-1. Black, residues identical in more than 30% of
sequences; gray, those homologous in more than 30% of sequences. Asterick, residues essential for the mediation of apoptosis by the human
TNFR1. D, residues corresponding to the site of the lpr mutation in the mouse Fas receptor. The residues are numbered with the start site
representing the first amino acid.
(C) Hydrophobicity plots of DR5 and DR4. Numbers refer to the position of the amino acid residues. HPhobic, hydorphobic; Hphilic, hydrophilic.
complex (Boldin et al., 1996; Chinnaiyan et al., 1996a; in Figures 3B and 3F, the FLICE-C360S mutant was able
to block apoptosis mediated by DR5, DR4, and DR3Muzio et al., 1996). To test whether DR5-induced apo-
ptosis also involves recruitment of FLICE (MACH1), we effectively. Finally, z-VAD-fmk and CrmA, two inhibitors
of proximal caspases, also blocked apoptosis mediatedtested the ability of a dominant-negative mutant of
FLICE (Boldin et al., 1996) containing a cysteine-to-ser- by DR5 in MCF7 cells (Figure 3B) (Tewari and Dixit, 1995;
Muzio et al., 1996). Thus, DR5 and DR4 resemble otherine substitution at the catalytic active site (FLICE-C360S
mutant) to block apoptosis mediated by DR5. As shown death domain±containing receptors in sharing the same
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binding to RIP and TRAF2 (Hsu et al., 1996a, 1996b).
However, no physical interaction could be demonstrated
between DR4 and either TRADD or RIP (Pan et al., 1997a);
based on the sequence homology between the death
domains of DR4 and DR5, DR5 was expected to behave
in a similar fashion. To resolve this discrepancy, we
decided to reexamine the possibility that TRADD may
be the adapter that binds to the death domains of DR5
and DR4 and mediates apoptosis and NF-kB activation.
Figure 2. Northern Blot Analysis of DR5 mRNA in Human Tissues We started by testing theability of an N-terminal deletion
Human multiple tissue Northern blots (Clontech) were probed with mutant of TRADD (ND-TRADD) to block NF-kB activa-
a DR5 encoding cDNA probe. PBL, peripheral blood leukocytes; tion by DR5, DR4, and DR3. This deletion construct
Sm. Intestine, small intestine.
lacks the N-terminal 102 amino acids and thus does not
possess a complete TRAF2-binding domain, but it does
possess a complete RIP/FADD-binding death domain
proximal and distal signaling molecules for transmitting (Hsu et al., 1996a, 1996b). A similar N-terminal deletion
the death signal. construct of TRADD (residues 25±312) was previously
shown to block TNFa-induced NF-kB activation in the
Both DR5 and DR4 Activate NF-kB 293 cells (Park and Baichwal, 1996). As shown in Figure
Activation of TNFR1 and DR3 has been shown to induce 4C, ND-TRADD could block NF-kB activation effectively
NF-kB activation, whereas DR4 has been shown to lack by all three death domain receptors. These results indi-
this activity (Tartaglia and Goeddel, 1992; Chinnaiyan et cate that DR5 and DR4 resemble DR3 and TNFR1 in
al., 1996a; Kitson et al., 1996; Marsters et al., 1996; using a TRADD-dependent pathway to activate NF-kB.
Bodmer et al., 1997; Pan et al., 1997a). To test whether
DR5 can induce NF-kB, we cotransfected different recep-
DR5 and DR4 Interact with FADD, TRADD, andtor constructs with a NF-kB-luciferase reporter plasmid
RIP in Coimmunoprecipitation Assaysand a lacZ expression plasmid into 293T cells. Overex-
To confirm the physical interactions of DR5 and DR4pression of DR5 led to significant activation of NF-kB
with the adapter molecules FADD, TRADD, and RIP,in 293T cells, whereas the two C-terminal deletion mu-
coimmunoprecipitation experiments were carried out.tants, DR5DCP and DR5DDD, as well as the L334N point
Both DR5 and DR4 could coimmunoprecipitate AU1-mutant, failed to do so (Figure 4A). Therefore, the death
FADD to the same extent as DR3 and Fas (Figure 5A).domain of DR5 is essential for both induction of
Coexpression of ND-TRADD did not lead to any furtherapoptosis and NF-kB activation. Based on the sequence
increase in the binding of FADD to any of the receptorshomology to DR4, we did not expect DR5 to induce NF-
(data not shown). These results suggest that either DR4kB activation. Our result led us to reexamine the ability
and DR5 can bind to FADD independent of TRADD orof DR4 to induce NF-kB. Contrary to the previous report
that the observed effect is due to the presence of endog-(Pan et al., 1997a), DR4 effectively activated NF-kB in
enous TRADD, which is not limiting in amount. Both DR4293T cells (Figure 4A). Thus, DR5 and DR4 resemble
and DR5 could also coimmunoprecipitate HA-taggedTNFR1 and DR3 in their ability to activate NF-kB.
ND-TRADD and RIP (Figures 5B, 5C and 5D). TheseWe also tested the ability of DR5, DR4, and DR3 to
results suggest that both DR4 and DR5 resemble TNFR1induce NF-kB activation in MCF7 cells (Figure 4B). While
and DR3 in involving FADD, TRADD, and RIP in theirDR3 could effectively activate NF-kB in these cells, DR5
signal-transduction pathway and that FADD is the com-and DR4 could do so only slightly. However, in the pres-
mon mediator of apoptosis by all known death domain±ence of CrmA, both DR5 and DR4 could effectively acti-
containing receptors.vate NF-kB, an effect comparable to that seen with DR3.
These results suggest that the relatively poor ability of
DR4 and DR5 to induce NF-kB in these cells issecondary Discussion
to their rapid induction of apoptosis, and they also indi-
cate that the ability of these receptors to activate NF- DR5 is the fifth death domain±containing member of the
kB is independent of their ability to induce apoptosis. TNFR family and is highly homologous to the TRAIL
receptor, DR4. Like other members of this family, the
extracellular domain of DR5 contains cysteine-rich pseu-Dominant-Negative TRADD Can Block NF-kB
Activation by DR5, DR4, and DR3 dorepeats that play a crucial role in binding to cognate
ligand (Smith et al., 1994). The extracellular domain ofAs demonstrated above, the death domain of DR5 is
responsible for the mediation of apoptosis as well as DR5 is most homologous to DR4 (58% identity; 70%
similarity) (Pan et al., 1997a). This high degree of homol-NF-kB activation. Previous studies have shown that the
death domains of TNFR1 and DR3 are similarly responsi- ogy extends to the cytoplasmic tail and the death do-
main as well, suggesting that DR5 and DR4 are moreble for both these activities, and these results can be
explained mechanistically by the ability of their death closely related evolutionarily to each other than to the
other members of this family and may represent a newdomains to recruit TRADD (Tartaglia et al., 1993; Kitson
et al., 1996). TRADD has the ability to activate the apo- subfamily among the TNFR family members.
DR5 possesses a highly conserved death domain inptotic pathway through FADD or the NF-kB pathway by
DR5, a New Member of the TNFR Family
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Figure 3. Induction of Apoptosis by DR5 Overexpression
(A) Induction of apoptosis in MCF7 cells by overexpression of either the full-length DR5 construct or various deletion or point mutant constructs.
The data (mean 6 standard deviation) are the percentage of round blue cells as a function of the total number of blue cells counted. A
representative of three independent experiments performed in duplicate.
(B) Inhibition of apoptosis in MCF7 cells by dominant-negative FADD (DN-FD), dominant-negative FLICE/MACHa1 (FL-C360S), CrmA, and
z-VAD-fmk (20 mM). A representative of three independent experiments performed in duplicate.
(C) Inhibition of DR5-, DR4-, and DR3-induced apoptosis by progressive, increasing amounts of DN-FADD (DN-FD) in 293T cells. Equal amounts
(150 ng) of each receptor were transfected with 150 ng, 750 ng, or 1500 ng of DN-FADD. The total amount of DNA in each transfection was
kept constant by adding vector plasmid DNA. A representative of two independent experiments performed in duplicate.
(D) Expression of DN-FADD and Myc-DR4 in 293T cells. Western analysis of 293T cells demonstrating the relative level of expression of the
Myc-DR4 construct and progressive, increasing amounts of the DN-FADD construct using Myc and FADD MAbs, respectively.
(E) Phase-contrast photomicrograph of 293T cells transfected with either expression constructs containing DR5, DR4, or DR3 and pcDNA3
vector plasmid or DN-FADD. Receptor to DN-FADD (or vector control) ratio, 1:10. Cells were stained with X-Gal, which stains the transfected
cells blue. Apoptotic cells have dark rounded appearance, show membrane blebs, and are lifting off from the plate. Original magnification,
4003.
(F) Inhibition of DR5, DR4, or DR3 induced apoptosis by dominant-negative FLICE (FLICE-C360S) in 293T cells. Receptors to FLICE-C360S
ratio, 1:5. A representative of five experiments performed in duplicate.
its cytoplasmic tail, and mutagenesis studies revealed the lpr mutation in the mouse Fas receptor effectively
abolished the ability of DR5 to induce apoptosis (Wata-that the death domain is indeed responsible for the in-
duction of apoptosis. Like other members of this family, nabe-Fukunaga et al., 1992; Itoh and Nagata, 1993; Tar-
taglia et al., 1993; Kitson et al., 1996). Several recenta leucine-to-asparagine point mutation at the site of
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Figure 4. DR5 and DR4 Activate NF-kB by a TRADD-Dependent Pathway
(A) Activation of NF-kB by DR5 and DR4. 293T cells were transfected in duplicate with the indicated receptor constructs (0.5 mg) along with
the NF-kB reporter construct (0.5 mg) (Berberich et al., 1994) and a lacZ reporter construct (0.2 mg) in a 24-well plate. Eighteen hours later,
luciferase activity was measured from one of the wells using the luciferase assay reagent (Promega) and following the manufacturer's
instructions. The cells in the other well were fixed with gluteraldehyde and stained with X-Gal to obtain the relative transfection efficiency.
Results are from three independent representative experiments (mean 6 standard deviation).
(B) Activation of NF-kB in the MCF7 cells. MCF7 cells were transfected in quadruplicate with the indicated receptor constructs (0.25 mg) along
with the NF-kB reporter construct (0.25 mg) (Berberich et al., 1994) and a lacZ reporter construct (0.2 mg) either in the absence or presence
of a crmA expression plasmid (0.25 mg). Twenty-four hours later, luciferase activity was measured from three wells as described above. The
cells in the fourth well were fixed with gluteraldehyde and stained with X-Gal to obtain the relative transfection efficiency and to confirm the
inhibition of cell death by CrmA. Results are from one of the two independent representative experiments (mean 6 standard deviation).
(C) (ND-TRADD) an N-terminal deletion mutant of TRADD (0.75 mg) blocks NF-kB activation by DR5, DR4, and DR3 (0.15 mg each). Receptor
to ND-TRADD ratio was 1:5. The total amount of plasmid was kept constant by adding empty vector DNA. Results (mean 6 standard deviation)
are from at least four independent experiments. Transfection and luciferase assay were performed as in Figure 4A.
studies have reported the occurrence of autoimmune mediated by death domain receptors will depend on the
level of expression of the endogenous FADD relativedisorders caused by point mutations in the death do-
main of the human Fas receptor that are capable of to the level of expression of the transfected DN-FADD
construct. Therefore, different cell lines, depending onblocking the function of the wild-type receptor in a
dominant-negative fashion (Fisher et al., 1995; Drappa their level of expression of endogenous FADD and the
relative transfection efficiency for the DN-FADD con-et al., 1996; Sneller et al., 1997). Future studies should
test whether point mutations in the death domain of struct, will have a quantitative difference in the ability
of DN-FADD to block apoptosis.DR5, similar to the L334Nmutant generated in this study,
occur naturally in the human population and whether We conducted our initial experiments with DN-FADD
in MCF7 cells and observed only a 2- to 3-fold reductionthey play a role in the pathogenesis of autoimmune
disorders. in apoptosis mediated by DR5, DR4, and DR3 (Figure
3B and data not shown). We chose 293T cells for ourThe high degree of sequence homology between the
death domains of DR5 and DR4 initially led us to believe subsequent studies, based on their high transfection
efficiency and their ability to replicate the transfectedthat DR5 mediates apoptosis by a FADD-independent
pathway as well. One unexpected result of our study plasmid as an episome leading to high-level expression
of the transfected genes. The importance of obtainingwas the ability of DN-FADD to block apoptosis mediated
by DR5 and DR4. While this manuscript was under pre- a sufficiently high-level expression of the transfected
DN-FADD construct is clearly evident from Figure 3C,liminary review, three additional studies were published
describing the signal transduction pathway utilized by where increasing amounts of the DN-FADD construct
led to a progressive decrease in the apoptosis mediatedDR4 or DR5 (Pan et al., 1997b; Sheridan et al., 1997;
Walczak et al., 1997). Whereas two of the studies sug- by all three death domain receptors. Notably, the other
positive study demonstrating the involvement of FADDgest that DR4 and DR5 mediate apoptosis by a FADD-
independent pathway (Pan et al., 1997b; Sheridan et in the signaling by DR5 utilized EBNA-positive CV1 cells,
which are also likely to lead to high level expressional., 1997), the third study agrees with our conclusion
(Walczak et al., 1997). The discrepancy among the differ- of the transfected DN-FADD construct (Walczak et al.,
1997).ent studies may be explained by the choice of the cell
lines and the relative level of expression of the trans- A related finding of our study was the ability of both
DR5 and DR4 to activate the NF-kB pathway in 293Tfected genes. The ability of DN-FADD to block apoptosis
DR5, a New Member of the TNFR Family
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Figure 6. Signal Transduction Pathways Used by TNFR1, DR3, DR4,
and DR5
Ligand-induced aggregationof the death domain±containing recep-
tors TNFR1, DR3, DR4, and DR5 lead to recruitment of TRADD
via death domain±death domain interaction. The death domain of
TRADD then recruits FADD, which leads to apoptosis by the subse-
quent recruitment and activation of FLICE/MACH1. The death do-
mains of the aggregated receptors can also recruit RIP directly or
indirectly via their interactions with TRADD. While the C-terminal
death domain of TRADD recruits RIP, its N-terminal domain recruits
TRAF2. TRAF2 can also be recruited to the receptors via its interac-
tion with RIP. Recruitment of TRAF2 and RIP leads to the activation
of the NF-kB pathway, which may protect against cell death. Stripes,
death domains; black, death effector domains; and gray, TRADD-
RIP-TRAF2 interacting domains.
Figure 5. Interactions of DR5 and DR4 with FADD, TRADD, and RIP
in the MCF7 cells and concluded that this phenomenon(A) DR5 and DR4 interact directly with FADD. 293T cells were
is cell-type dependent. These negative results are prob-transfected with AU1 epitope-tagged FADD along with Myc-tagged
DR5, DR4, DR3, or Fas/Apo-1. Myc-tagged receptors from the cell ably secondary to the rapid induction of apoptosis by
lysates wereprecipitated using control (Flag) beads (c) orMyc beads TRAIL or DR4/DR5 in the MCF7 cells, as demonstrated
(a myc), and coprecipitating FADD was detected using a combina- by the ability of both these receptors to activate NF-kB
tion of FADD and AU1 antibodies (top). Western blot analysis on the
in the presence of CrmA in the present study (Figuretotal cell-lysate demonstrates the expression of the various tagged
4B). Furthermore, the ability of DR4 and DR5 to activatereceptors (bottom).
NF-kB in the presence of CrmA suggests that they in-(B) DR5 and DR4 interact directly with TRADD. 293T cells were
transfected with HA epitope-tagged ND-TRADD along with 6X-His duce NF-kB expression independent of their ability to
epitope-tagged DR5 or DR4. His-tagged receptors from the cell induce apoptosis.
lysates were immunoprecipitated using a cocktail of three anti-His An N-terminal deletion mutant of TRADD (ND-TRADD)
antibodies, and coprecipitating ND-TRADD was detected using a
is able to partially block NF-kB activation by DR5, DR4,combination of TRADD and HA MAbs.
and DR3. This deletion construct lacks the N-terminal(C) DR5 interacts directly with RIP. 293T cells were transfected with
102 amino acids and therefore is missing a completeHA epitope-tagged RIP along with Myc-tagged DR5. Myc-tagged
receptor from the cell lysates was precipitated using control (Flag) TRAF2-binding domain, but it does possess a complete
beads (c) or Myc beads (a myc), and coprecipitating RIP-HA was death domain and probably works by competing with
detected using a HRP-conjugated HA MAb. the endogenous full-length TRADD for binding to the
(D) DR4 interacts directly with RIP. 293T cells were transfected with
death domains of the receptors (Figure 6). On beingHA epitope-tagged RIP along with 6X-His epitope-tagged DR4 or
recruited to theaggregated death domain receptor com-empty vector. His-tagged receptors from the cell lysates were pre-
plex, this construct will be unable to bind directly andcipitated using Ni-sepharose beads, and coprecipitating RIP-HA
was detected using a combination of RIP and HA antibodies. recruit TRAF2. However, some TRAF2 might still be re-
cruited to the aggregated death receptors via a RIP±
TRAF2 interaction, which explains only partial inhibition
of NF-kB by this construct (Figure 6). Thus, ND-TRADDcells, a finding in agreement with a recently published
report (Sheridan et al., 1997). Although a previous study possesses partial agonist activity for NF-kB activation,
a conclusion also supported by the weak activation offailed to demonstrate effective NF-kB activation by DR4
in the 293 cells (Pan et al., 1997a), a careful examination NF-kB observed in our experiments involving the trans-
fection of ND-TRADD construct alone (Figure 4C). Areveals an approximately 10-fold induction of NF-kB by
DR4 in that study as well. In an independent test involv- similar N-terminal deletion construct of TRADD (resi-
dues 25±312), which possesses an incomplete TRAF2ing treatment of the MCF7 cells with TRAIL or TNFa,
Pan et al. (1997a) did not observe significant NF-kB domain, has been previously shown to activate NF-kB
partially while blocking TNFa±induced NF-kB activationactivation by TRAIL either. This result is in agreement
with the recent report by Sheridan et al. (1997) that also (Park and Baichwal, 1996). Therefore, our result with
ND-TRADD confirms the importance of the N-terminalfailed to demonstrate NF-kB induction by DR4 or DR5
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site at the 39 end and then were ligated to a modified pSectagTRAF2 binding domain in the activation of NF-kB by the
A vector (Invitrogen) containing a Myc or an MRG-6X-His epitopedeath domain±containing receptors (Park and Baichwal,
downstream of a murine Ig k-chain signal peptide. Epitope-tagged1996).
versions of DR4 (amino acids 106-468), DR3 (amino acids 27-418),
Finally, DR3, DR4, and DR5 were able to coimmuno- and Fas/Apo1 (amino acids 19-335) were constructed similarly ex-
precipitate FADD. Our results with DR3 are in agreement cept that the 59 primer for amplifying Fas contained an EcoRI site.
The DR5-L334N was generated by mutagenesis of the 6X-His-DR5with a previous report demonstrating its ability to immu-
plasmid using the Quickchange kit (Stratagene), following the manu-noprecipitate FADD even in the absence of the cotrans-
facturer's instructions. A FLICE-C360S mutantwas constructed sim-fected TRADD (Bodmer et al., 1997). However, two other
ilarly. DR5DCP and DR5DDD lack 192 and 134 C-terminal aminostudies could demonstrate only a weak coimmunopre-
acids, respectively, and were generated by creating a polymerase
cipitation or no coimmunoprecipitation of FADD with chain reaction generated XbaI site or by taking advantage of a
DR3 (Chinnaiyan et al., 1996a; Kitson et al., 1996). Simi- naturally occurring SmaI site in the DR5 sequence, respectively.
ND-TRADD-HA (lacking the N-terminal 102 amino acids) and RIP-HAlarly, in contrast to the present study, two recent studies
plasmids were constructed by using custom primers designed tofailed to demonstrate any interaction between DR4/DR5
generate a C-terminal HA tag and using cDNAs derived from humanand FADD, TRADD, or RIP (Pan et al., 1997a, 1997b).
breast and fetal spleen mRNA as template, respectively. The se-This discrepancy among various studies might be due
quences of all the above constructs were confirmed by automated
to the difference in the endogenous level of expression fluorescent sequencing.
of other adapter proteins that might stabilize the tran-
sient and unstable interactions between the receptors Transient Transfection Assays
For transient transfection assays, 0.8±1 3 105 MCF7 or BHK cellsand the adapter protein being tested. For example,
were cotransfected with 1 mg of various test plasmids and 200 ngTRADD has been reported to enhance the interaction
of a lacZ expression plasmid in a 24-wellplate using 3 ml of Superfectbetween RIP and TNFR1 or DR3 (Chinnaiyan et al.,
(Qiagen) in Dulbelco's modified Eagle's medium supplemented with1996a; Hsu et al., 1996a), and we have observed similarly
10% fetal calf serum, following themanufacturer's instructions. After
that the interaction between RIP and DR4 or DR5 can 3 hr, 0.5 ml of fresh Dulbelco's modified eagle's medium supple-
be enhanced by the coexpression of FADD (unpublished mented with 10% fetal calf serum was added. Twenty-four to 36
hr later, cells were fixed with gluteraldehyde (0.05% in phospate-data). A difference in the conditions of cell lysis or im-
buffered saline) and stained with 5-bromo-4-chloro-3-indoxyl-b-D-munoprecipitation might also contribute to this dis-
galactosidase (X-Gal). Cells were examined at high magnificationcrepancy.
under a phase-contrast microscope and apoptotic cells identifiedIn summary, both DR4 and DR5 resemble TNFR1 and
on the basis of their dark rounded appearance, membrane ªblebs,º
DR3 in mediating FADD-dependent apoptosis and acti- and lifting off from the plate. 293T (1 3 105) cells were transfected
vating the NF-kB pathway. However, our ability to detect by calcium phosphate precipitation in a 24-well plate.
the activation of the NF-kB pathway may be hampered
by the rapid induction of apoptosis by these receptors. Coimmunoprecipitation and Western Blot Analysis
Monoclonal antibodies against human FADD, TRADD, and RIP wereFinally, the extent of NF-kB activation triggered by these
obtained from Transduction Laboratories. Antibodies against thereceptors may be influenced by the susceptibility of their
AU1 and HA epitope tags were obtained from Babcoand Boehringerhost cells to apoptosis and therefore may be cell-type
Mannheim, respectively. Myc beads and Flag beads were obtained
and context- dependent. from Santa Cruz Laboratories and IBI Kodak, respectively. For
studying in vivo interaction between the receptors and various
Experimental Procedures adapters, 2 3 106 293T cells were plated in a 10 mm plate and
cotransfected the following day with 5 mg of various epitope-tagged
Cloning of DR5 cDNA and Sequence Analysis receptor plasmids, 5 mg of various adapter plasmids, 2 mg of CrmA
Two EST clones (IMAGE Consortium clones 650744 and 664665) plasmid, and 0.5 mg of a green fluorescent protein (GFP) encoding
encoding a new member of the TNFR superfamily were identified plasmid (pEGFP-C1) (Clontech) by calcium phosphate coprecipita-
by searching the database of expressed sequence tags (dbEST) for tion. The following day cells were examined under a fluorescent
sequences sharing homology to the extracellular of human TNFR1 microscope to ensure equal transfection efficiency as determined
receptor. Initial attempts to obtain the plasmids from these clones by the expression of the GFP. Twenty-four to 36 hr posttransfection,
failed. Therefore, based on the sequence of these EST clones, poly- cells were lysed in 1 ml of lysis buffer containing 0.1% Triton X-100,
merase chain reaction primers were designed, and 59 and 39 RACE 20 mm sodium phosphate (pH 7.4), 150 mm NaCl, and 1 EDTA
was performed on human fetal brain Marathon ready cDNA (Clon- free protease inhibitor tablet per 10 ml (Boehringer Mannheim). Cell
tech) using the Marathon cDNA amplification kit (Clontech) and fol- lysate was precleared by incubation with Flag beads.
lowing the manufacturer's instructions. RACE fragments were For immunoprecipitation, precleared cell lysate (500 ml) was incu-
cloned using a TA cloning kit (Invitrogen) and sequenced on an bated with 10 ml of Myc beads or control (Flag) beads for 1 hr at
automated fluorescent sequencer to obtain the sequence of the 48C. Beads were washed twice with lysis buffer; twice with a wash
full-length cDNA. Percentage identity and similarity scores were buffer containing 1% Triton X-100, 20 mm sodium phosphate (pH
obtained by using the Gap program (Genetic Computer Group, Mad- 7.4), 500 mM NaCl, and again with lysis buffer. Bound proteins were
ison, WI). Hydrophobicity plots were generated by using the Pepplot eluted by boiling for 3 min in SDS loading buffer, separated by SDS-
program (Genetic Computer Group, Madison, WI). polyacrylamide gel electrophoresis, transferred to a nitrocellulose
membrane, and analyzed by Western blot. For immunoprecipitation
Northern Blot Analysis of MRG-6X-His tagged receptors, cells were lysed in a 1 ml of lysis
Northern blot analysis was performed by using human multiple- buffer containing 1% Triton-X 100, 20 mm sodium phosphate (pH
tissue Northern blot (Clontech). The blot was hybridized under high 7.4), 150 mm NaCl, and 1 EDTA free-protease inhibitor tablet per
stringency conditions with a radiolabeled DR5-encoding cDNA 10 ml. A cocktail of three monoclonal antibodies (MAbs) (MRG-
probe according to the instructions of the manufacturer. 4Xhis, Penta-His, and Tetra-His [Qiagen]) was used for immunopre-
cipitation. For precipitation using Ni-sepharose, cell lysates were
incubated for 1 hr with 20 ml of Ni-sepharose beads precoated withExpression Vectors
To construct Myc and 6X-His epitope-tagged receptors, amino 1% bovine serum albumin in a buffer containing 1% Triton-X 100,
20 mm sodium phosphate (pH 7.4), 500 mM NaCl, and EDTA-freeacids 51-411 of DR5 were amplified using pfu polymerase (Strata-
gene) with a primer containing a BamHI site at the 59 end and a SalI protease inhibitor cocktail. Beads were washed extensively with the
DR5, a New Member of the TNFR Family
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above buffer supplemented with 20 mM imidazole and the bound Dominant interfering Fas gene mutations impair apoptosis in a hu-
man autoimmune lymphoproliferative syndrome. Cell 81, 935±946.protein subsequently eluted and analyzed by SDS-polyacrylamide
gel electrophoresis and Western blot as described above. Gruss, H.J., and Dower, S.K. (1995). Tumor necrosis factor ligand
superfamily: involvement in the pathology of malignant lymphomas.
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